Key statistics
On Monday, Ultragenyx Pharmaceutical Inc (RARE:NSQ) closed at 23.02, 25.04% above the 52 week low of 18.41 set on Dec 29, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 22.54 |
|---|---|
| High | 23.19 |
| Low | 22.51 |
| Bid | 22.50 |
| Offer | 23.39 |
| Previous close | 23.39 |
| Average volume | 1.89m |
|---|---|
| Shares outstanding | 96.63m |
| Free float | 93.58m |
| P/E (TTM) | -- |
| Market cap | 2.26bn USD |
| EPS (TTM) | -5.83 USD |
Data delayed at least 15 minutes, as of Mar 02 2026 21:00 GMT.
More ▼
- Ultragenyx to Participate at Investor Conferences in March
- Ultragenyx Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application (BLA) for DTX401 AAV Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)
- Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Ultragenyx Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Update
- Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2025 Financial Results and Corporate Update
- Ultragenyx Announces Positive Longer-Term Data Demonstrating Treatment with UX111 Gene Therapy Results in Sustained, Significant Reductions in CSF-HS and Continued Meaningful Improvements in Clinical Function Across Multiple Developmental Domains in Children with Sanfilippo Syndrome (MPS IIIA)
- Ultragenyx Resubmits Biologics License Application for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA) to U.S. FDA
- Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Ultragenyx Provides Financial and Business Updates at J.P. Morgan Annual Healthcare Conference
- Ultragenyx to Present at the 44th Annual J.P. Morgan Healthcare Conference
More ▼
